No­var­tis ex­pands Covid-19 vac­cine man­u­fac­tur­ing deal with Pfiz­er/BioN­Tech; Exacis links with CCRM for NK cell ther­a­pies

BioN­Tech has signed an agree­ment with No­var­tis to ex­pand fill-fin­ish sup­port for the com­pa­ny’s Covid-19 vac­cine — made in col­lab­o­ra­tion with Pfiz­er in Slove­nia.

The Ljubl­jana, Slove­nia ster­ile man­u­fac­tur­ing site will be used to fill at least 24 mil­lion dos­es in 2022, and un­der the terms of the agree­ment, No­var­tis will take bulk mR­NA ac­tive in­gre­di­ent from BioN­Tech, fill that in­to vials, and ship it back to them for dis­tri­b­u­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER